@FiercePharma: Pfizer cops chase criminals in fake drug trade. Article | Follow @FiercePharma
> Eli Lilly plans to create 100 finance jobs at a European services center in Cork, Ireland, over the next 12 months. Report
> Longtime Merck KGaA executive Bernd Reckmann is expected to be brought in to run the company's new Millipore division when the $6 billion buyout is complete, a Millipore executive tells the Boston Herald. Story
> Allergan said U.K. drug regulators became the first in the world to approve the wrinkle treatment Botox for prevention of migraines. Report
> K-V Pharmaceutical may be delisted from the New York Stock Exchange after falling three months behind in filing quarterly and annual reports, the specialty drug company said Thursday. Article
> Pfizer has invested $100 million in the expansion of its Singapore plant that makes nutritional products for infants and children, increasing its capacity by 50 percent. Update
> The FDA has warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating healthcare professionals and patients about the potential risks. Release
> HHS Secretary Kathleen Sebelius said Thursday that she would provide $25 million more to help states buy life-saving medications for people with HIV or AIDS. Article
> Shire said it has filed a patent infringement suit against Indian generic drug developer Cadila Healthcare over the bowel disorder drug Lialda. Story
Biotech News
@FierceBiotech: Merck to shutter eight R&D facilities, cuts 15,000 jobs in global restructuring. Article | Follow @FierceBiotech
@JohnCFierce: Sanofi is planning to set up HQ for new cancer division in Cambridge, MA, adding 300 jobs. Article | Follow @JohnCFierce
> PacBio unveils software developer's network. Report
> Genzyme hits Anika with patent suit. Item
> Report: PregLem tests IPO waters. Story
And Finally... The discovery of an antibody that binds to certain brain receptors could reduce the side effects of a common stroke drug and buy additional time in which to use it. Report